Neurocrine Biosciences, Inc. (NASDAQ:NBIX) TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 12:40 PM EDT
Company Participants
Kyle Gano – CEO & Director
Sanjay Keswani – Chief Medical Officer
Todd Tushla
Conference Call Participants
Philip Nadeau – TD Cowen, Research Division
Presentation
Philip Nadeau
TD Cowen, Research Division
Good afternoon, and welcome to TD Cowen’s Neuropsych Summit. I’m Phil Nadeau, one of the biotech analysts here at TD Cowen, and it’s my pleasure to moderate a fireside chat with Neurocrine Biosciences. We have with us today, Kyle Gano, the Chief Executive Officer; Sanjay Keswani, the Chief Medical Officer; and Todd Tushla, the VP of Investor Relations.
Question-and-Answer Session
Philip Nadeau
TD Cowen, Research Division
Guys, first, I thought we’d start with maybe a brief overview of Neurocrine’s strategy for developing and commercializing drugs for neuropsychiatric conditions. In particular, maybe which indications is Neurocrine most interested in? And what types of targets will Neurocrine prioritize?
Kyle Gano
CEO & Director
Thanks, Phil. I’ll take that question, and thanks for having us here this morning. Always a pleasure to get together. Your question is actually timely, it’s timely for a couple of reasons. One is, as you probably heard from us over the course of the past year, our intentions and being deliberate and really changing our view on R&D strategy. So that’s point number one. Number two, we have an R&D Day coming up in December on the 16th, and you’ll hear more about how that evolution is playing out 1 year in.
But coming back specifically to your question, the aspects that are new to our strategy are severalfold. One of them is if you look at the pipeline today, it’s largely been in-licensed through business development, and that’s something that will still be a big part of Neurocrine
#Neurocrine #Biosciences #NBIX #Presents #Cowens #5th #Annual #Mechanisms #Neuropsychiatry #Epilepsy #Summit #Transcript